Cargando…
Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain
Romiplostim, a thrombopoietin-receptor agonist (TPO-ra), is a highly effective option in primary immune thrombocytopenia (ITP), with 80–90% of patients achieving platelet responses after few weeks of treatment. The evidence showing remissions, that is, sustained platelet counts after romiplostim dis...
Autores principales: | Mingot-Castellano, María-Eva, Grande-García, Carlos, Valcárcel-Ferreiras, David, Conill-Cortés, Clara, de Olivar-Oliver, Loreto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485313/ https://www.ncbi.nlm.nih.gov/pubmed/28695025 http://dx.doi.org/10.1155/2017/4109605 |
Ejemplares similares
-
Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
por: Vlachaki, Efthymia, et al.
Publicado: (2011) -
Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia
por: Lim, Hyun Ji, et al.
Publicado: (2020) -
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
por: Soff, Gerald A., et al.
Publicado: (2019) -
PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022) -
Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)